- Quotes
- Dashboard
- Chart
- Historical Prices
- Options
- News & PR
- News
- Market Currents
- Press Releases
- Coverage
- Cramer
- Top Analysts
- Business Intelligence
- Transcripts
- Events
- Key Developments
- Earnings
- History & Projected
- Consensus
- Peer Earnings
- Filings
- SEC Filings
- Annual Report
- Financials
- Income Statement
- Balance Sheet
- Cash Flow
52wk high:
52wk low:
EPS:
PE:
Div Rate:
Yield:
Market Cap:
Volume:
TRGT Market Currents
more »
-
May 3 Targacept (TRGT): Q1 EPS of $0.07 beats by $0.32. Revenue of $22.9M (-41% Y/Y). (PR)
Comment![Earnings, Healthcare]
TRGT in Focus
more »
TRGT Related Articles
more »
TRGT News
more »
-
at MarketWatch.com (Mar 20, 2012)
-
at MarketWatch.com (Dec 20, 2011)
-
at CNBC.com (Dec 13, 2011)
-
at CNBC.com (Nov 15, 2011)
-
at MarketWatch.com (Nov 8, 2011)
TRGT Press Releases and Filings
more »
-
Business Wire (May 3, 2012)
-
Business Wire (Apr 25, 2012)
-
Business Wire (Apr 25, 2012)
-
Business Wire (Apr 24, 2012)
-
Business Wire (Apr 10, 2012)
TRGT Latest Transcript
more »
TRGT Cramer
more »
-
Wed, Nov 16, 2011
-
Sun, Nov 8, 2009
TRGT Instablog posts
more »
TRGT vs. ETF Alternatives
Company Description
We are a biopharmaceutical company engaged in the design, discovery and development of NNR Therapeutics™, a new class of drugs for the treatment of diseases and disorders of the central nervous system. Our NNR Therapeutics selectively target neuronal nicotinic receptors, or NNRs. NNRs are found... More
